Prelude TherapeuticsPRLD
Fair Value
US$3
Share price06 Mar
US$5.5585.0% overvalued intrinsic discount
1Y537.93%
7D13.27%
Future Returns Will Depend On JAK2 Program Validation And Incyte Milestones
AN
Analyst Low Target compiles bearish analysts opinions to create narratives which represent one standard deviation below the consensus price target, using forecasted revenue and earnings figures, as well as the transcripts of earnings calls.
Published
06 Mar 26
Views
24
Not Invested